Kyverna Therapeutics shares are trading higher after the company and ElevateBio announced a manufacturing agreement for both U.S. commercial and global clinical supply of miv-cel, autologous CD19-directed CAR T-cell therapy.
192.22 +4.44 [+2.36%]
Stocks · News reference
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ:KYTX) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Kyverna Therapeutics, ElevateBio Announce Manufacturing Agreement For Both U.S. Commercial And Global Clinical Supply Of Miv-Cel, Kyverna’s Autologous CD19-Directed CAR T-Cell Therapy
Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, and ElevateBio, a technology-driven advanced therapy contract
8-K filing — Kyverna Therapeutics, Inc. (KYTX)
Filed: 2026-07-27 AccNo: 0001193125-26-316916 Size: 227 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits